格卡瑞韦/哌仑他韦治疗8周在初治丙型肝炎病毒感染患者中的整合分析:安全且有效
该整合分析汇总8项2期或3期试验,评估格卡瑞韦/哌仑他韦8周方案在初治基因1-6型丙型肝炎病毒(HCV)感染无肝硬化或代偿期肝硬化患者中的疗效与安全性。意向治疗人群持续病毒学应答率(SVR12)为97.6%,改良意向治疗人群为99.3%;治疗中出现不良事件发生率为58%,严重不良事件为2%。
要点
- 初治HCV基因1-6型无肝硬化或代偿期肝硬化患者,格卡瑞韦/哌仑他韦8周方案SVR12达97.6%(意向治疗)。
- 排除基因3型合并代偿期肝硬化患者后,SVR12在意向治疗人群为97.6%,改良意向治疗人群为99.4%。
- 治疗中出现不良事件发生率58%,最常见为头痛(12%)和乏力(12%),严重不良事件2%。
核心结论
- 8项试验的汇总分析显示,格卡瑞韦/哌仑他韦8周治疗对初治HCV基因1-6型感染患者(伴或不伴肝硬化)有效且耐受性良好。
研究设计与样本
- 汇总8项2期或3期试验,纳入接受格卡瑞韦/哌仑他韦8周治疗的初治HCV基因1-6型感染、无肝硬化或代偿期肝硬化患者,共1248例,其中343例(27%)有肝硬化。
主要发现
- 意向治疗人群SVR12为97.6%(1218/1248),改良意向治疗人群为99.3%(1218/1226)。
- 排除基因3型合并代偿期肝硬化患者后,意向治疗人群SVR12为97.6%,改良意向治疗人群为99.4%。
- 意向治疗人群发生8例病毒学失败(无肝硬化患者7例,肝硬化患者1例)。
- 病毒学失败与晚期肝病标志物或特定人群(当前饮酒、阿片替代治疗、注射吸毒史、严重肾损伤)无关。
- 治疗中出现不良事件发生率为58%,最常见(>10%)为头痛(12%)和乏力(12%);严重不良事件和导致停药的不良事件分别报告于2%和不足1%的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The direct-acting antiviral combination glecaprevir/pibrentasvir has been approved by the Food and Drug Administration for 8 weeks of treatment in treatment-naïve patients with hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. We performed an integrated analysis of data from trials to evaluate the overall efficacy and safety of 8 weeks of glecaprevir/pibrentasvir in treatment-naïve patients without cirrhosis or with compensated cirrhosis. METHODS: We pooled data from 8 phase 2 or phase 3 trials of treatment-naïve patients with HCV genotype 1 to 6 infections, without cirrhosis or with compensated cirrhosis, who received 8 weeks of glecaprevir/pibrentasvir. RESULTS: Of 1248 patients, 343 (27%) had cirrhosis. Most patients were white (80%) and had HCV genotype 1 infection (47%) or genotype 3 infection (22%); the median age was 54 years. Overall rates of sustained virologic response at post-treatment week 12 were 97.6% (1218 of 1248) in the intention to treat (ITT) and 99.3% (1218 of 1226) in the modified ITT populations. When we excluded patients with genotype 3 infections with compensated cirrhosis (consistent with the European label), rates of sustained virologic response at post-treatment week 12 were 97.6% in the ITT and 99.4% in the modified ITT populations. Eight virologic failures (7 in patients without cirrhosis and 1 in a patient with cirrhosis) occurred in the ITT population. Virologic failure was not associated with markers of advanced liver disease or populations of interest (current alcohol use, opioid substitution therapy, history of injection-drug use, and severe renal impairment). Treatment-emergent adverse events (AEs) occurred in 58% of patients. The most frequent AEs (>10%) were headache (12%) and fatigue (12%). Serious AEs and AEs that led to glecaprevir/pibrentasvir discontinuation were reported in 2% and less than 1% of patients, respectively. CONCLUSIONS: In a pooled analysis of data from 8 trials, we found that 8 weeks of treatment with glecaprevir/pibrentasvir is efficacious and well tolerated in treatment-naïve patients with HCV genotype 1 to 6 infections, with or without cirrhosis.
引用
- Zuckerman E, Gutierrez JA, Dylla DE, et al. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. Clin Gastroenterol Hepatol. 2020. PMID: 32621971. doi:10.1016/j.cgh.2020.06.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。